
    
      A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine
      as Second-Line or Third-Line Treatment in Patients With Advanced Triple-Negative Breast
      Cancer (NAN trail)
    
  